HZNP Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 2.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Horizon Therapeutics Public Insider Trading History Chart

This chart shows the insider buying and selling history at Horizon Therapeutics Public by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40M-$20M$0$20M$40MTotal Insider BuyingTotal Insider Selling

Horizon Therapeutics Public Share Price & Price History

Current Price: $116.30
Price Change: +0.30 (1.20%)
As of 10/6/2023 01:00 AM ET

This chart shows the closing price history over time for HZNP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

SEC Filings (Institutional Ownership Changes) for Horizon Therapeutics Public (NASDAQ:HZNP)

80.37% of Horizon Therapeutics Public stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at HZNP by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2B$0$2BTotal InflowsTotal Outflows
Horizon Therapeutics Public logo
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Read More on Horizon Therapeutics Public

Today's Range

Now: $116.30
Low: $116.30
High: $116.30

50 Day Range

MA: $115.72
Low: $112.60
High: $116.30

52 Week Range

Now: $116.30
Low: $60.03
High: $116.38

Volume

N/A

Average Volume

2,498,525 shs

Market Capitalization

$26.63 billion

P/E Ratio

62.19

Dividend Yield

N/A

Beta

1.03